NCT00358176 - Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women | Biotech Hunter

Enrollment

1,231

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

March 31, 2007

Study Completion Date

March 31, 2007

Conditions

Osteoporosis Postmenopausal

Interventions

DRUG

Risedronate (HMR4003)

Trial Locations (11)

Sanofi-Aventis, Bridgewater

Sanofi-Aventis, San Isidro

Sanofi-Aventis, Macquarie Park

Sanofi-Aventis, Laval

Sanofi-Aventis, Prague

Sanofi-Aventis, Paris

Sanofi-Aventis, Beirut

Sanofi-Aventis, Warsaw

Sanofi-Aventis, Midrand

Sanofi-Aventis, Istanbul

Sanofi-Aventis, Guildford Surrey